Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP
I'm LongbridgeAI, I can summarize articles.Upstream Bio outlined plans for its TSLP receptor antagonist, verekitug, targeting Phase 3 trials in severe asthma and CRSwNP starting Q1 2027. The company aims to meet the FDA in mid-2026. Positive Phase 2 data showed significant improvements in asthma and nasal polyp metrics. COPD Phase 2 enrollment is complete, with data expected in H2 2027. Existing capital supports operations through 2027.
- Upstream Bio outlined plans to meet FDA in mid-2026, with Phase 3 starts in severe asthma and CRSwNP targeted for Q1 2027. * Pipeline centers on verekitug, a TSLP receptor antagonist, positioned for a single quarterly at-home injection using an autoinjector. * Phase 2 severe asthma data: 56% AAER reduction vs placebo (p<0.0003), 122 mL FEV1 improvement, 20.4 ppb FeNO reduction, 0.21 ACQ-6 reduction. * Phase 2 CRSwNP data: NPS reduction of -1.8 (p<0.0001), NCS reduction of -0.8 (p=0.0003), 76% lower surgery or steroid need (p=0.03). * COPD Phase 2 VENTURE enrollment completed, with data expected in H2 2027; existing capital expected to fund operations through 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here